Understand the source comparison
Best Peptides for Parkinson's Disease: Compound Comparison
This table compares the leading research peptides for Parkinson's disease based on mechanism, administration route, evidence quality, and practical considerations. Cerebrolysin Delivers neurotrophic factors (BDNF, NGF, CNTF) that activate PI3K/Akt survival pat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the leading research peptides for Parkinson's disease based on mechanism, administration route, evidence quality, and practical considerations.
- Cerebrolysin
- Delivers neurotrophic factors (BDNF, NGF, CNTF) that activate PI3K/Akt survival pathways and inhibit apoptosis
- Intravenous infusion
- Human RCTs + extensive preclinical data
- 28-day trial: 6.2-point UPDRS improvement vs 1.8 placebo; effects sustained at 12 weeks
- Strongest clinical evidence but requires IV administration; most viable for institutional research settings
- P21
- BDNF receptor (TrkB) agonist. Activates MAPK/ERK signaling independent of endogenous BDNF levels
- Subcutaneous injection
- Preclinical only (rodent models)
- MPTP model: preserved 45% more dopaminergic neurons; reduced microglial activation by 30–40%
- Promising neuroprotective profile but no human safety data; dose translation from mice to humans remains speculative
- Dihexa
- Potentiates HGF/Met receptor interaction; upregulates synaptophysin and PSD-95 to increase synaptic density
- Oral administration
- Preclinical (cognitive endpoints)
- Aged rats: 60% improvement in spatial memory; >50% oral bioavailability
- Targets cognitive decline rather than motor symptoms; oral route offers practical advantage for long-term protocols